Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M H Frick

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Circulation|January 1, 1992
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatmentV Manninen, L Tenkanen, P Koskinen, et al.
American Heart Journal|April 1, 1992
Leukocytes as a coronary risk factor in a dyslipidemic male populationM Mänttäri, V Manninen, P Koskinen, et al.
Journal of Internal Medicine|January 1, 1994
The Helsinki Heart Study: an 8.5-year safety and mortality follow-upJ K Huttunen, O P Heinonen, V Manninen, et al.
Annals of Medicine|April 1, 1991
The Helsinki Heart Study: central findings and clinical implicationsJ K Huttunen, V Manninen, M Mänttäri, et al.
Atherosclerosis|June 28, 2001
Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatmentF Karpe, M R Taskinen, M S Nieminen, et al.
Thrombosis and Haemostasis|April 1, 2000
Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapyA Hamsten, M Syvänne, A Silveira, et al.
Controlled Clinical Trials|February 1, 1997
A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lopid Coronary Angiography TrialM Syvänne, M R Taskinen, Nieminen, et al.
Annals of Internal Medicine|February 15, 1992
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart StudyP Saikku, M Leinonen, L Tenkanen, et al.
Circulation|October 23, 1997
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study GroupM H Frick, M Syvänne, M S Nieminen, et al.
British Journal of Clinical Pharmacology|January 1, 1986
A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertensionM H Frick, P Halttunen, P Himanen, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Circulation|January 1, 1992
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatmentV Manninen, L Tenkanen, P Koskinen, et al.
American Heart Journal|April 1, 1992
Leukocytes as a coronary risk factor in a dyslipidemic male populationM Mänttäri, V Manninen, P Koskinen, et al.
Journal of Internal Medicine|January 1, 1994
The Helsinki Heart Study: an 8.5-year safety and mortality follow-upJ K Huttunen, O P Heinonen, V Manninen, et al.
Annals of Medicine|April 1, 1991
The Helsinki Heart Study: central findings and clinical implicationsJ K Huttunen, V Manninen, M Mänttäri, et al.
Atherosclerosis|June 28, 2001
Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatmentF Karpe, M R Taskinen, M S Nieminen, et al.
Thrombosis and Haemostasis|April 1, 2000
Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapyA Hamsten, M Syvänne, A Silveira, et al.
Controlled Clinical Trials|February 1, 1997
A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lopid Coronary Angiography TrialM Syvänne, M R Taskinen, Nieminen, et al.
Annals of Internal Medicine|February 15, 1992
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart StudyP Saikku, M Leinonen, L Tenkanen, et al.
Circulation|October 23, 1997
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study GroupM H Frick, M Syvänne, M S Nieminen, et al.
British Journal of Clinical Pharmacology|January 1, 1986
A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertensionM H Frick, P Halttunen, P Himanen, et al.
Pageof 14